Difference between revisions of "NF-kappa-B inhibitor alpha"
m (IκB moved to NF-kappa-B inhibitor alpha) |
m |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
| − | |||
| − | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 8: | Line 6: | ||
|- | |- | ||
| Synonyms | | Synonyms | ||
| − | | | + | | I-kappa-B-alpha |
| − | I-kappa-B-alpha | ||
|- | |- | ||
| Determination type | | Determination type | ||
| Line 32: | Line 29: | ||
| PRDGL''KK''ERLLD | | PRDGL''KK''ERLLD | ||
LHSIL''K''ATNYN | LHSIL''K''ATNYN | ||
| + | |||
PSTRI''QQ''QLGQL | PSTRI''QQ''QLGQL | ||
| + | |||
DCVFGG''Q''RLTL | DCVFGG''Q''RLTL | ||
|- | |- | ||
| Structure | | Structure | ||
| − | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1IKN 1IKN] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| Line 50: | Line 49: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:49, 10 March 2015
| NF-kappa-B inhibitor alpha | |
|---|---|
| Substrate peptide name | NF-kappa-B inhibitor alpha |
| Synonyms | I-kappa-B-alpha |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | P25963 |
| Reactive glutamines | Q266, Q267, Q313 |
| Reactive lysines | K21, K22, K177 |
| Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
| Structure | 1IKN |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:16987813 |
| Notes | |
